Show Less
You do not have access to this content

EU LAW OF COMPETITION AND TRADE IN THE PHARMACEUTICAL SECTOR

PABLO FIGUEROA, ALEJANDRO GUERRERO

This book provides a systematic analysis of the law and practice of EU competition and trade in the pharmaceutical sector.     Authored by leading private practitioners, economists, scholars and high-level officials at competition regulators, this work provides valuable insider knowledge on the application of law and policies to the pharmaceutical industry.  The work contains extensive commentary on the legislation and the latest case law and administrative precedents in this sector, at both EU and national level, including certain significant jurisdictions (e.g., the US, China). Coverage of various key developments includes the recent pay-for-delay antitrust investigations, the perennial issues around parallel trade, and an examination of mergers among pharmaceutical companies and medical devices manufacturers. In addition to the legal analysis, it offers vital economic and business perspectives to ensure that the reader has the full range of tools with which to prepare for cases and conduct transactions within the pharmaceutical industry.
Show Summary Details
This content is available to you

TABLE OF CASES

EUROPEAN UNION

Court of First Instance

AC-Treuhand v. Commission, T-99/04, ECLI:EU:T:2008:256, [2008] ECR II-1501 8.204

Airtours v. Commission, Case T-342/99 20.40

Atlantic Containers Lines AB v. Commission, Case T191/98, [2003] ECR II-3275 5.69

Bayer AG v. Commission of the European Communities, Case T-41/96, [2000] ECR I-3383 10.52

BPB Industries plc v. Commission, Case T–65/89, ECLI:EU:T:1993:31 20.41

Compagnie Maritime Belge Transports v. Commission, Case T-24/93 20.40

Corus v. Commission, Case T-48/00, EU:T:2004:219 3.176

European Night Services v. Commission, Joined cases T-374/94, T-375/94, T-384/94 and T-388/94, ECLI:EU:T:1998:198 3.85

Fenin v. Commission, Case T-319/99, ECLI:EU:T:2003:50 17.22, 17.23, 17.25

GlaxoSmithKline Services v. Commission, Case T-168/01, [2006] ECR II-2969 10.101, 17.44

Irish Sugar v. Commission, Case T-228/97 20.42

LR AF 1998 A/S v. Commission, Case T23/99, ECLI:EU:T:2002:75, [2002] ECR II-1705 8.68

O2 (Germany) v. Commission, Case T-328/03, ECLI:EU:T:2006:116 3.18

Court of Justice (ECJ)

AC-Treuhand AG v. Commission, Case C-194/14 P, [2015] ECLI:EU:C:2015:717 8.201

Actavis Group PTC EHF v. Sanofi, Case C-443/12, ECLI:EU:C:2013:833 12.106, 12.114

Actavis Group PTC EHF, Actavis UK Ltd v. Boehringer Ingelheim Pharma GmbH & Co. KG, Case C-577/13, ECLI:EU:C:2015:165 12.10, 12.114

AGS Assedic, Case C-235/95, ECLI:EU:C:1998:365 11.46

AKZO Chemie BV v. Commission, Case C-62/86, ECLI:EU:C:1991:286 15.24

Allen and Hanburys v. Generics, Case C-434/85, ECLI:EU:C:1987:520 11.30

Allianz Hungária Biztosító Zrt v. Gazdasági Versenyhivatal, Case C-32/11, EU:C:2013:160, [2013] 4 CMLR 25 3.17, 3.152, 18.72, 18.73, 18.74

AOK-Bundesverband v. Ichthyol Gesellschaft Cordes, Joined cases C-264/01, ECLI:EU:C:2004:150, [2004] ECR I–02493 17.23

Apothekerkammer des Saarlandes, Joined cases C-171/07 and C-172/07, ECLI:EU:C:2009:316 11.25, 11.27

Aragonesa, Joined cases C-1/90 and C-176/90, ECLI:EU:C:1991:327 11.27

Aseprofar and Edifa v. Commission, Case T-247/04, ECLI:EU:T:2005:327, [2005] ECR II-3449 10.60

Association of Pharmaceutical Importers and others, Joined cases 266/87 and 267/87, ECLI:EU:C:1989:205 11.40

Astellas Pharma Inc. v. Polpharma SA Pharmaceutical Works, C-661/13, ECLI:EU:C:2014:588 12.88

Astrazeneca AB v. Comptroller General of Patents, Designs and Trade Marks, Case C-617/12, ECLI:EU:C:2013:761 12.118

AstraZeneca v. Commission, Case C-457/10 P, ECLI:EU:C:2012:770 1.89, 1.91, 1.98, 1.100, 3.229, 5.11, 5.12, 5.26, 5.36, 5.38, 5.53, 5.76, 5.79, 5.80, 5.83, 5.84, 5.88, 5.92, 5.98, 5.102, 11.58, 17.14, 18.64

Autortiesību un komunicēšanās konsultāciju ag´entūra/Latvijas Autoru apvienība v. Konkurences padome (“Latvian Copyright”), Case C-177/16, EU:C:2017:689 15.117, 15.119

Aventis v. Kohlpharma, Case C-433/00, ECLI:EU:C:2002:510 11.39

Basset, Case C-402/85, ECLI:EU:C:1987:197 5.23

BAT v. Commission, C35/83, ECLI:EU:C:1985:32 4.107

Bayer & Maschinenfabrik Hennecke v. Heinz Süllhöfer, Case C-65/86, ECLI:EU:C:1988:448 ECJ 3.179, 4.101

Beef Industry Development and Barry Brothers, Case C-209/07, ECLI:EU:C:2008:643 3.13

Béguelin Import Co v. Import Export SA GL, Case C22/71, ECLI:EU:C:1971:113 3.21

Bertelsmann and Sony Corp v. IMPALA, Case C-413/06 P 20.40

Biogen Inc v. Smithkline Beecham Biologicals SA, Case C-181/95, ECLI:EU:C:1997:32 12.112

Boehringer Ingelheim, Case C-348/04, ECLI:EU:C:2007:249 11.36, 11.39

Boehringer v. Swingward, Case C-143/00, ECLI:EU:C:2002:246 11.39

Bouchara, Case C-25/88, ECLI:EU:C:1988:551 11.35

Bristol-Myers Squibb v. Paranova, Joined cases C-427/93, C-429/93 and C-436/93, ECLI:EU:C:1996:282 11.29, 11.37, 11.38, 11.39

Centrafarm BV and Adriaan de Peijper v. Sterling Drug Inc., Case C-15/74, ECLI:EU:C:1974:114, [1974] ECR 1147 11.16, 11.29

Centrafarm and de Peijper v. Winthrop, Case C-16/74, ECLI:EU:C:1974:115 11.16, 11.29

Centrafarm v. American Home Products, Case C-3/78, EU:C:1978:174 4.14

CEPSA, Case C-279/06, ECLI:EU:C:2008:485 11.46

CICRA and Others v. Renault, Case C-53/87, ECLI:EU:C:1988:472 5.25, 5.88

Class International BV v. Colgate-Palmolive Co, Case C-405/03, EU:C:2005:616 9.27

Coditel v. Ciné-Vog Films, Case C-262/81, ECLI:EU:C:1982:334 4.79

Commission v. Austria, Case C-424/99, ECLI:EU:C:2001:642 11.43

Commission v. Austria, Case C-150/00, ECLI:EU:C:2004:237, [2004] ECR I-3887 13.21

Commission v. Austria, Case C-311/07, ECLI:EU:C:2008:431 11.43

Commission v. Bayer, Joined cases C-2/01 P and C-3/01 P, ECLI:EU:C:2004:2, [2004] ECR I-122 10.7, 10.50

Commission v. Belgium, Case C-249/88, ECLI:EU:C:1991:121 11.43, 11.45, 11.48

Commission v. Finland, Case C-229/00, ECLI:EU:C:2003:334 11.43

Commission v. France, Case C-381/93, ECLI:EU:C:1994:370 11.53

Commission v. France, Case C-212/03, ECLI:EU:C:2005:313 11.53

Commission v. Germany, Case C-141/07, ECLI:EU:C:2008:492 11.27

Commission v. Germany, Case C-62/90, ECLI:EU:C:1992:169 11.27, 11.53

Commission v. Germany, Case C-387/99, [2004] ECR I-3751 13.21

Commission v. Ireland, Case C-95/09, ECLI:EU:C:2010:394 5.67

Commission v. Italy, Case C-56/87, ECLI:EU:C:1988:295 11.43

Commission v. Stichting Administratiekantoor Portielje, Case C-440/11 P, ECLI:EU:C:2013:514 8.10

Compagnie maritime belge transports SA v. Commission, Case C-395/96 P 20.42

Compagnie Royale Asturienne des Mines (CRAM) and Rheinzink GmbH v. Commission of the European Communities, Joined cases 29/83 and 30/83, ECLI:EU:C:1984:130 3.13

Consten and Grundig v. Commission, Case 56/64, [1966] ECR 299 4.13, 4.79, 5.23

Daiichi Sankyo Company v. Comptroller General of Patents, Designs and Trade Marks, Case C-6/11, ECLI:EU:C:2011:781 12.102

Dalmine v. Commission, Case T-50/00, ECLI:EU:T:2004:220 3.176

Dansk R.rindustri A/S v. Commission, Joined Cases C-189/02 P, C-202/02 P, C-205/02 P to C-208/02 P and C-213/02 P, ECLI:EU:C:2005:408, [2005] ECR I-5425 8.97

de Peijper, Case 104/75, ECLI:EU:C:1976:67 11.18

Delattre, Case C-369/88, ECLI:EU:C:1991:137, [1991] ECR I–01487 11.25, 11.27, 11.38, 13.19, 13.21

Delimits v. Henninger Brau AG, Case C-234/89, ECLI:EU:C:1991:91 3.19, 20.29

Deutsche Parkinson Vereinigung, Case C-148/15, ECLI:EU:C:2016:776 11.44

DIP SpA v. Comune di Bassano del Grappa, LIDL Italia Srl v. Comune di Chioggia and Lingral Srl v. Comune di Chiogg, Case C-140/94 20.40

DocMorris, Case C-322/01, ECLI: EU:C:2003:664 11.27

Dohme, Case C-400/09), ECLI:EU:C:2011:519 11.39

Duphar BV v. The Netherlands State, Case 238/82, ECLI:EU:C:1984:45, [1984] ECR 523 10.33, 11.48

Eli Lilly and Co Ltd v. Human Genome Sciences Inc, Case C-493/12, ECLI:EU:C:2013:835 12.105, 12.106

Eurim-Pharm, Case C-347/89, ECLI:EU:C:1991:148 11.27, 11.36

Eurim-Pharm v. Beiersdorf, Boehringer Ingelheim and Farmitalia, Joined cases C-71/94, C-72/94 and C-73/94, ECLI:EU:C:1996:286 11.37, 11.38, 11.39

F Hoffmann-La Roche Ltd v. Autorita Garante della Concorrenza e del Mercato, Case C-179/16, ECLI:EU:C:2018:25 3.24, 3.229, 3.230, 3.233, 3.235, 3.255

Farmitalia Carlo Erba Srl, Case C-392/97, ECLI:EU:C:1999:416 12.101, 12.102, 12.104, 12.105

FENIN v. Commission, Case C-205/03 P, ECLI:EU:C:2006:453, [2006] ECR I-6295 17.22, 17.23, 17.25

Ferring v. Eurim-Pharm, Case C-172/00, ECLI:EU:C:2002:86 11.17, 11.18, 11.32

Football Association Premier League, Joined cases C-403/08 and C-429/08, ECLI:EU:C:2011:631 3.102

General Motors BV v. Commission, Case C-551/03 P, ECLI:EU:C:2006:639 3.13

Generics (UK) Ltd v. Synaptech Inc, Case C-427/09, ECLI:EU:C:2011:520 12.96

Generics (UK), Case C-307/18 3.88, 3.103, 3.146, 3.147, 3.148, 3.150, 3.161, 3.162, 15.95

Generics and Harris v. Smith Kline, Case C-191/90, ECLI:EU:C:1992:407 11.30

Generics v. Smith Kline, Case C-316/95, ECLI:EU:C:1997:347 11.33

Georgetown University and Others v. Comptroller General of Patents, Designs and Trade Marks, Case C-422/10, ECLI:EU:C:2011:776 12.102, 12.114

Georgetown University v. Octrooicentrum Nederland, Case C-484/12, ECLI:EU:C:2013:828 12.114

GlaxoSmithKline Services, Joined cases C-501/06 P, C-513/06 P, C-515/06 P and C-519/06 P, ECLI:EU:C:2009:610 1.57, 3.17, 3.50, 3.120, 3.152, 17.44

Groupement des cartes bancaires, Case C-67/13 P, EU:C:2014:2204 3.2, 3.13, 3.16, 8.10, 18.72, 18.73, 18.74

GSK v. Commission, Joined cases C-501/06 P, C-513/06 P, C-515/06 P and C-519/06, ECLI:EU:C:2009:610, [2009] ECR I-9291 10.55, 11.58, 11.60

Hässle v. Ratiopharm GmbH, Case C-127/00, ECLI:EU:C:2003:661 12.117

Hoffmann-La Roche & Co AG v. Commission, Case 85/76, [1979] ECR 461 5.66, 20.36, 20.42

Hoffmann-La Roche v. Centrafarm, Case C-102/77, ECLI:EU:C1978:108 4.14, 5.23, 11.29, 11.39

Höfner v. Macrotron, Case C-41/90, ECLI:EU:C:1991:161, [1991] I-1979 17.23

IAZ, Joined cases C-96-102, 104, 105, 108 and 110/82, ECLI:EU:C:1983:310 3.13

IMS Health GmbH & Co OHG v. NDC Health GmbH & Co KG, Case C418/01 ECLI:EU:C:2004:257 5.23, 5.25, 20.16, 20.42

Intel v. Commission, Case C-413/14 P 20.42

Joined cases C-352/07 to C-356/07, C-365/07 to C-367/07 and C-400/07 Menarini Industrie Farmaceutiche Riunite Srl v. Ministero della Salute and Agenzia Italiana del Farmaco ECLI:EU:C:2009:217, [2009] ECR I-2495 10.35, 11.43

Kingdom of Spain and Italian Republic v. Council of the European Union, Joined cases C-274/11 and C-295/11, ECLI:EU:C:2013:240 12.17

Kohll, Case C-158/96, ECLI:EU:C:1998:171 11.50, 11.51, 11.52

Kohlpharma, Case C-112/02, ECLI:EU:C:2004:208 11.18

Konkurrensverket v. TeliaSonera Sverige, Case C-52/09, ECLI:EU:C:2011:83 3.6

Laboratoires Lyocentre, Case C-109/12, ECLI:EU:C:2013:626 13.21, 13.22

Langnese-Iglo v. Commission, Case C-279/95 P, ECLI:EU:C:1998:447 20.29

Louis Erauw-Jacquéry v. La Hesbignonne, Case C27/87, ECLI:EU:C:1988:183 4.79

Lundbeck v. Commission, Case C-591/16 P 3.88, 3.105, 3.106, 3.107, 15.97

Magill TV Guide, Re, Joined cases C-241/91 P and C-242/91 P, ECLI:EU:C:1995:98 5.23

Medeva BV v. Comptroller General of Patents, Designs and Trade Marks, Case C-322/10, ECLI:EU:C:2011:773 12.99, 12.102, 12.104, 12.109

Medical Ltd and Macfarlan Smith Ltd, Case C-324/93, EU:C:1995:84, [1995] ECR I-563 10.34

Merck and Others v. Europharm, Joined cases C-267/95 and C-268/95, ECLI:EU:C:1996:468 4.14, 11.30

Merck Sharp & Dohme Corp. v. Deutsches Patent- und Markenamt, Case C-125/10, ECLI:EU:C:2011:812 12.120

Merck v. Stephar, Case 187/80, ECLI:EU:C:1981:180 11.16

Merck, Sharp & Dohme v. Paranova, Case C-443/99, ECLI:EU:C:2002:245 11.39

Monteil and Samanni, Case C60/89, ECLI:EU:C:1991:138 11.25, 11.38

Montex Holdings Ltd v. Diesel SpA, Case C-281/05, ECLI:EU:C:2006:709 9.27

MPA Pharma GmbH v. Rhône-Poulenc Pharma GmbH, Case C-232/94, ECLI:EU:C:1996:289 11.39

Neurim Pharmaceuticals Ltd v. Comptroller – General of Patents, Case C-130/11, ECLI:EU:C:2012:489 12.97

Nicolas Decker and Caisse de Maladie des Employés Privés, Case C-120/95, ECLI:EU:C:1998:167, [1998] ECR I-1831 10.34, 11.50, 11.52

Novartis AG v. Actavis UK Ltd, C-442/11, ECLI:EU:C:2012:66 12.99

Novartis AG v. Comptroller-General of Patents, Designs and Trade Marks and Ministre de l’Économie v. Millennium Pharmaceuticals Inc, Joined cases C207/03 and C252/03, ECLI:EU:C:2005:245 12.118

Nungesser v. Commission, Case C-258/78, ECLI:EU:C:1982:211 3.102, 4.13, 4.73, 4.79, 4.91, 4.92

NV Nederlandsche Banden-Industrie Michelin v. Commission, Case 322/81 5.69

Orfanopoulos, Joined cases C-482/01 and C-493/01, ECLI:EU:C:2004:262 11.46

Orifarm and Paranova Danmark v. Merck Sharp & Dohme Corp (formerly Merck & Co Inc), Joined cases C-400/09 and C-207/10, ECLI:EU:C:2011:519 11.39

Ottung v. Klee & Weilbach A/S, Case 320/87, ECLI:EU:C:1989:195 4.66, 4.67

Paranova Läkemedel AB and Others v. Läkemedelsverket, Case C-15/01, ECLI:EU:C:2003:256 11.18

Paranova Oy, Case C-113/01, ECLI:EU:C:2002:755 11.18

Pharmacia & Upjohn SA v. Paranova A/S, Case C379/97, ECLI:EU:C:1999:494 11.39

Pharmon v. Hoechst, Case 19/84, ECLI:EU:C:1985:304 11.30

Philips and Nokia, Joined cases C-446/09 and C-495/09, ECLI:EU:C:2011:796 9.27, 9.28, 9.29, 9.30

Philips and Nokia, Joined cases C-446/09 and C-495/09, EU:C:2011:796 9.26

Pohl-Boskamp, Case C-317/05, ECLI:EU:C:2006:684 11.43

Polo/Lauren Co LP v. Dwidua Langgeng Pratama International Freight Forwarders, Case C-383/98, EU:C:2000:193 9.27

Poucet and Pistre v. AGF and Cancava, Joined cases C-159/91 and C–160/91, ECLI:EU:C:1993:63, [1993] ECR I-637 17.24

Pronuptia de Paris, Case C-161/84 4.92

Rhône-Poulenc, Case C-94/98, ECLI:EU:C:1999:614 11.17, 11.18, 11.32

Roquette Freres, Case C-94/00, ECLI:EU:C:2002:603 3.6

Roussel Laboratoria BV v. The Netherlands, Case 181/82, ECLI:EU:C:1983:352, [1983] ECR 3849 10.32, 10.33, 11.42, 11.43, 11.46, 11.58

Sandoz Prodotti Farmaceutici SpA v. Commission of the European Communities, Case C-277/87, ECLI:EU:C:1990:6, [1990] ECR I-45 10.49

Schumacher, Case 215/87, ECLI:EU:C:1989:111 11.27, 11.53

Seattle Genetics Inc v. Österreichisches Patentamt, Case C-471/14, ECLI:EU:C:2015:659 12.119

Servier and Others v. Commission, Case T-691/14, ECLI:EU:T:2018:922 3.88, 3.103, 3.105, 3.106, 3.132, 3.137, 3.138, 3.139, 3.140, 3.161, 3.170, 3.171, 3.207, 3.208, 3.212, 3.215, 3.239, 3.240, 4.15

Smith & Nephew Primecrown, Case C-201/94, ECLI:EU:C:1996:432 11.18

Société Technique Miniere v. Maschinenbau Ulm GmbH, Case 56/65, ECLI:EU:C:1966:38 3.13, 3.45

Sot. Lélos kai Sia EE and Others v. GlaxoSmithKline AEVE Farmakeftikon Proionton, Joined cases C-468 to 478/06, ECLI:EU:C:2008:504, [2008] ECR I-7139 10.7, 10.70, 10.71, 10.88, 11.58, 11.60, 17.60

Spain v. Council of the European Union, Case C-147/13, ECLI:EU:C:2015:299 12.17

Spain v. European Parliament and Council of the European Union, Case C-146/13, ECLI:EU:C:2015:298 12.17

Synetairismos Farmakopoion Aitolias&Akarnanias (SYFAIT) v. GlaxoSmithKline plc, Case C-53/03, ECLI:EU:C:2005:333, [2005] ECR I-4609 ECJ 10.63, 10.64, 10.102, 11.60

Synthon BV v. Merz Pharma GmbH & Co. KGaA, Case C-195/09, ECLI:EU:C:2011:518 12.96

T-Mobile Netherlands, Case C-8/08, EU:C:2009:343 3.17, 3.152

The Queen and Secretary of State for the Home Department, ex parte Evans Medical Ltd and Macfarlan Smith Ltd, Case C-324/93, ECLI:EU:C:1995:84 10.34

Union royale belge des sociétés de football association and Others v. Bosman, Case C-415/93, EU:C:1995:293 3.69

United Brands Company v. Commission of the European Communities, Case 27/76, ECLI:EU:C:1978:22 15.30, 15.109, 15.117

University of Queensland and CSL Ltd v. Comptroller General of Patents, Designs and Trade Marks, Case C-630/10, ECLI:EU:C:2011:780 12.102

Völk, Case C-5/69, ECLI:EU:C:1969:35 3.21

Volvo v. Veng, Case 238/87, ECLI:EU:C:1988:477 5.23, 5.25, 5.88

Wellcome Foundation v. Paranova, Case C-276/05, ECLI:EU:C:2008:756 11.39

Windsurfing International, Case C-193/83, EU:C:1986:75 ECJ 3.139, 3.175, 4.16, 4.65, 4.92

Yeda Research and Development Company Ltd y Aventis Holdings Inc v. Comptroller General of Patents, Designs and Trade Marks, C-518/10, ECLI:EU:C:2011:779 12.102

Yves Saint Laurent v. Javico International, Case C306/96, ECLI:EU:C:1998:173 4.77

EFTA

Pharmaq v. Intervet, Case E-16/14 12.110

General Court

Arrow Group and Arrow Generics v. Commission, Case T-467/13, ECLI:EU:T:2016:450 17.41

AstraZeneca AB v. Commission, Case T-321/05, [2007] ECLI:EU:T:2010:266, [2010] ECR II-2805 1.89, 1.91, 1.98, 1.100, 5.5, 5.36, 6.3, 15.67, 17.14, 18.64, 20.16, 20.18, 20.33, 20.42, 20.51

Biogaran v. Commission, Case T-677/14, ECLI:EU:T:2018:910 3.88

E.ON Ruhrgas v. Commission, T-360/09, ECR, EU:T:2012:332 3.86

EAEPC v. Commission, Case T-574/14, ECLI:EU:T:2018:605 17.46

European Association of Euro Pharmaceutical Companies (EAEPC) v. European Commission, Case T-574/14 (pending) 10.61

Generics (UK) v. Commission, Case T-469/13, ECLI:EU:T:2016:454 17.41

Krka v. Commission, Case T-684/14, ECLI:EU:T:2018:918 3.88

Lundbeck v. European Commission, Case T-472/13, ECLI:EU:T:2016:449 2.7, 2.82, 2.120, 2.121, 2.131, 2.133, 2.134, 3.77, 3.86, 3.87, 3.88, 3.98, 3.102, 3.103, 3.105, 3.106, 3.107, 3.108, 3.110, 3.111, 3.112, 3.114, 3.116, 3.118, 3.121, 3.125, 3.146, 3.166, 3.167, 3.168, 3.173, 3.174, 3.175, 3.177, 3.178, 3.207, 15.97, 17.41, 18.44, 18.47, 18.48, 18.50, 18.51, 18.52, 18.53, 18.55, 18.59, 18.60, 18.61, 18.72, 18.74, 18.75, 18.76

Lupin v. Commission, Case T-680/14, ECLI:EU:T:2018:908 3.88

Merck v. Commission, Case T-470/13, ECLI:EU:T:2016:452 17.41

Mylan Laboratories v. Commission, Case T-682/14, ECLI:EU:T:2018:907 3.88

Niche Generics v. Commission, Case T-701/14, ECLI:EU:T:2018:921 3.88

Sun Pharmaceutical Industries v. Commission, Case T-460/13, ECLI:EU:T:2016:453 17.41

Teva UK v. Commission, Case T-679/14, ECLI:EU:T:2018:919 3.88

Unichem Laboratories Ltd v. Commission, Case T-705/14, ECLI:EU:T:2018:915 3.88

Visa Europe Ltd v. Commission, Case T-461/07, EU:T:2011:181 3.85, 3.87, 3.106, 15.97

Xellia Pharmaceuticals and Alpharma v. Commission, Case T-471/13, ECLI:EU:T:2016:460 17.41

European Commission

Antitrust

AstraZeneca, COMP/A.37.507/F3 1.89, 1.91, 1.98, 1.100, 3.229, 4.107, 5.27, 5.36, 15.18, 15.67, 17.14, 18.4, 18.43

Boehringer, COMP/B2/39246 18.62

Cephalon, COMP/AT.39686 3.59, 18.43, 18.62, 18.63

E-books, COMP/39.847 20.42

EAEPC/Pfizer, COMP/38293/B2 17.46

EAEPC/Pfizer, COMP/39243/B2 17.46

Fentanyl, COMP/AT.39685 2.78, 2.123, 2.124, 2.125, 2.126, 2.127, 2.128, 3.13, 3.59, 3.87, 3.91, 3.184, 3.188, 3.189, 3.190, 3.191, 3.195, 3.196, 3.198, 3.199, 3.200, 3.201, 3.202, 3.204, 15.76, 18.4, 18.43, 18.55

Glaxo Wellcome, IV.36957 10.56, 17.46

Industrial bags, COMP/38354 8.43

Lundbeck, COMP/AT.39226 2.7, 2.20, 2.33, 2.36, 2.64, 2.69, 2.78, 2.79, 2.80, 2.110, 2.111, 2.112, 2.113, 2.114, 2.116, 2.117, 2.118, 2.119, 2.122, 3.59, 3.77, 3.98, 3.105, 3.106, 3.107, 15.76, 17.41, 18.4, 18.43, 18.44, 18.45, 18.46, 18.47

Perindopril (Servier), COMP/AT.39612 1.90, 1.91, 2.7, 2.21, 2.34, 2.47, 2.64, 2.70, 2.78, 2.80, 2.94, 2.95, 2.96, 2.97, 2.98, 2.99, 2.100, 2.101, 2.102, 2.103, 2.104, 2.105, 2.106, 2.107, 2.109, 2.119, 2.130, 3.59, 3.77, 3.91, 3.98, 3.103, 3.124, 3.127, 3.141, 3.142, 3.143, 3.145, 3.152, 3.154, 3.155, 3.157, 3.158, 3.160, 3.247, 15.76, 15.102, 18.4, 18.43, 18.56

Spain Pharma/Pfizer, COMP/39184/B2 17.46

Spain Pharma/Pfizer, COMP/39257/B2 17.46

Swedish Match Sverige/Skandinavisk Tobakskompagni, COMP/B–2/38.381 20.42

Velcro/Alpix, IV/4.204 4.14, 4.73, 4.92

Windsurfing International, IV/29.395 4.14, 4.16, 4.65, 4.73, 4.89, 4.92, 4.101

Decisions

AOIP/Beyrard, IV/26.949, Commission Decision of 2 December 1975 4.14, 4.44, 4.65, 4.67, 4.86, 4.101

Bayer/Gist-Brocades, IV/27.073, Commission Decision of 15 December 1975 4.97, 4.101

BBC Brown Boveri, IV/32.368, Commission Decision of 11 October 1988 4.77

Beecham/Park Davis, IV/28.796, Commission Decision of 17 January 1979 4.55

Boussois/Interpane, IV/31.302, Commission Decision of 15 December 1986 4.46, 4.67, 4.73, 4.80, 4.96, 4.97

Breeders’ rights – maize seed, IV/28.824, Commission Decision of 21 September 1978 4.14, 4.91

Burroughs-Delplanque, IV/5.400, Commission Decision of 22 December 1971 4.46, 4.74

Campari, IV/28.173, Commission Decision of 23 December 1977 4.46, 4.77, 4.84, 4.86, 4.91, 4.92

Davidson Rubber, IV/17.545, Commission Decision of 9 June 1972 4.46, 4.75, 4.79, 4.98, 4.101

Delta Chemie/DDD, IV/31.498, Commission Decision of 13 October 1988 4.46, 4.75, 4.86, 4.96

Elopak/Metal Box – Odin, IV/32.009, Commission Decision of 13 July 1990 4.31, 4.46, 4.58, 4.73

Generics/AstraZeneca, AT.37507, Commission decision of 15 July 2006 3.246

Johnson & Johnson/Guidant, M.3687, Commission decision of 25 August 2005 3.246

Kabelmetal-Luchaire, IV/21.353, Commission Decision of 18 July 1975 4.75, 4.77, 4.82, 4.96, 4.97

Mitchell Cotts/Sofiltra, IV/31.340, Commission Decision of 17 December 1986 4.46, 4.75, 4.83, 4.86, 4.87, 4.97

Moosehead/Whitbread, IV/32.736, Commission Decision of 23 March 1990 4.91, 4.100

Ordre National des Pharmaciens en France (ONP), AT.39510, Commission decision of 8 December 2010 3.47

Pasteur Mérieux – Merck, IV/34.776, Commission Decision of 6 October 1994 4.17, 4.55, 4.57, 4.73

Penneys, IV/29.246, Commission Decision of 23 December 231977 4.107

Raymond – Nagoya, IV/26.813, Commission Decision of 9 June 1972 4.14, 4.46, 4.77, 4.97

Rich Products/Jus-rol, IV/31.206, Commission Decision of 22 December 1987 4.46, 4.67, 4.73, 4.91, 4.96, 4.97

Rio Tinto Alcan, AT.39230, Commission Decision of 20 December 2012 4.37, 4.92, 4.93

Vaessen/Moris, IV/29.290, Commission Decision of 10 January 1979 4.14, 4.101

Vitamins, AT.37512, Commission decision of 21 November 2001 3.206

Mergers

3i/Vedici Groupe, COMP/M.5805 6.39

A&C/Grosspharma, COMP/M.2573 6.39, 6.43

Abbott/Guidant, COMP/M.4150 7.43, 7.45, 7.46, 7.100

Abbott/Solvay Pharmaceuticals, COMP/M.5661 6.50, 7.13, 7.16, 7.19, 7.20, 7.24, 7.98

Actavis/Allergan, COMP/M.7480 7.58

Agfa-Gevaert/Sterling, IV/M.1432 7.25, 7.26, 7.32

Akzo/ICI, COMP/M.4779 6.62

Alliance Boots/Andreae-Noris Zahn, COMP/M.6044 6.39

Alliance Boots/Cardinal Health, COMP/M.4301 6.39, 6.43

Angelini/Phoenix/JV, COMP/M.2432 6.39

Apax/Kinetic Concepts, COMP/M.6343 7.51, 7.71, 7.73, 7.92, 7.114

Apax/Mölnlycke, COMP/M.3816 7.69, 7.73, 7.76, 7.80, 7.82, 7.114, 7.115

APHL/L&R/Netcare General Healthcare Group, COMP/M.4229 6.39, 7.69, 7.73, 7.74, 7.75, 7.76, 7.80, 7.92, 7.114

APW/APSA/Nordic Capital/Capio, COMP/M.4367 6.39, 7.61, 7.62, 7.69, 7.73, 7.76, 7.78, 7.80, 7.81, 7.82, 7.92, 7.114

Astra/Zeneca, COMP/M.1403 6.27, 6.30

Bain/Hoechst – Dade Behring, IV/M.954 7.13, 7.19

Barclays/RBS/Hillary, COMP/M.5548 6.39

Baxter International/Gambro, COMP/M.6851 6.62, 7.55, 7.78, 7.95, 7.115

Bayer Healthcare/Roche (OTC Business), COMP/M.3544 6.10, 6.62

Bayer/Chiron Diagnostics, IV/M.1325 7.13, 7.18, 7.19, 7.22, 7.24

Becton Dickinson and Company/CareFusion, COMP/M.7459 7.56, 7.63, 7.64, 7.65, 7.66, 7.70, 7.114

Boston Scientific/Guidant, COMP/M.4076 7.43, 7.47, 7.48

Bridgepoint/EdRCP, COMP/M.7309 7.57, 7.58, 7.92, 7.114

Brocacef/Mediq Netherlands, M.7494 6.43

Celesio/Sainsbury’s UK pharmacy business, M.7721 6.43

Ciba-Geigy/Sandoz, IV/M.737 6.27, 6.30

CVC/Teva’s Women’s Health Business, M.8675 6.9, 6.11, 6.12, 6.13, 6.17, 6.40, 6.47

Danaher/Beckman Coulter, COMP/M.6175 7.13, 7.18, 7.20

Dentsply/Sirona, M.7822 7.57, 7.111

DSM/Roche Vitamins, COMP/M.2972 6.65

DSM/Sinochem/JV, COMP/M.6113 6.32

EQT VI/BSN Medical, COMP/M.6560 7.61, 7.69, 7.72, 7.75, 7.80, 7.81, 7.92, 7.114

EQT VI/Terveystalo Healthcare, COMP/M.7058 7.61, 7.62, 7.72, 7.73, 7.74, 7.75, 7.92, 7.114

Facebook/Whatsapp, COMP/M.7217 20.14, 20.46

FEDIFAR/Pfizer, COMP/38215/B2 17.46

Fresenius/Helios, COMP/M.4010 7.55, 7.92, 7.114

Galenica/Fresenius Medical Care/Vifor Fresenius Medical Care Renal Pharma JV, COMP/M.6091 7.55, 7.65, 7.92, 7.114

GE/Abbott Diagnostics Division, COMP/M.4569 7.13, 7.18, 7.19, 7.55, 7.81,7.92, 7.114, 7.115

GE/Amersham, COMP/M.3304 7.25, 7.25, 7.26, 7.27, 7.28, 7.30, 7.31, 7.55, 7.81, 7.92, 7.115

GE/Instrumentarium, COMP/M.3083 7.26, 7.32, 7.52, 7.53, 7.78, 7.81, 7.101, 7.112

Glaxo Wellcome/SmithKline Beecham, COMP/M.1846 6.15, 6.27, 6.30

GlaxoSmithKline/Novartis Vaccines Business (excl. Influenza)/Novartis Consumer Health Business, COMP/M.7276 7.60

Google/DoubleClick, COMP/M.4731 20.14

Hoffmann La Roche/Boehringer Mannheim, IV/M.950 7.11, 7.13, 7.18, 7.19, 7.22, 7.24, 7.105, 7.115

IMS Health/Cegedim, COMP/M.7337 20.16, 20.17, 20.18, 20.19, 20.49, 20.52

Investor/Morgan Stanley/Mölnlycke, COMP/M.4579 7.69, 7.73, 7.78, 7.80, 7.82, 7.92, 7.114

J&J/Actelion, COMP/M.8401 6.66

Johnson & Johnson/DePuy, IV/M.1286 7.33, 7.35, 7.104

Johnson & Johnson/Guidant, COMP/M.3687 6.61, 7.43, 7.44, 7.45, 7.46, 7.47, 7.48, 7.55, 7.100, 7.115

Johnson & Johnson/Pfizer Consumer Healthcare, COMP/M.4314 6.62, 6.63

Johnson & Johnson/Synthes, COMP/M.6266 6.61, 7.11, 7.33, 7.38, 7.39, 7.40, 7.41, 7.42, 7.90, 7.96, 7.115

Kodak/Imation, IV/M.1298 7.11, 7.25, 7.26

La Roche/Syntex, IV/M.457 7.13, 7.19

Lonza Group/Capsugel, COMP/M.8362 6.38

Lonza/Teva/JV, COMP/M.5479 6.24

Medtronic/Covidien, COMP/M.7326 6.62, 7.11, 7.43, 7.44, 7.46, 7.49, 7.78, 7.85, 7.94, 7.114, 7.115

Merck/Schering-Plough, COMP/M.5502 6.50

Merck/Sigma-Aldrich, COMP/M.7435 6.33

Monsanto/Pharmacia & Upjohn, COMP/M.1835 6.30, 15.21

Mylan/Abbott EPD-DM, COMP/M.7379 6.5, 6.11, 6.12, 6.15, 6.19, 6.25, 6.27, 6.32, 6.34, 6.47, 6.50, 6.62

Mylan/Perrigo, M.7645 6.13, 6.27, 6.47

Nordic Capital/ConvaTec, COMP/M.5190 7.73, 7.82, 7.99

Nordic Capital/GHD Verwaltung, COMP/M.7323 6.39, 6.43, 7.61, 7.67, 7.73, 7.77, 7.114

Nordic Capital/Mölnlycke Clinical/Kolmi, IV/M.1075 7.69, 7.80

Novartis/Alcon, COMP/M.5778 6.14, 6.15, 6.63

Novartis/GlaxoSmithKline Oncology Business, COMP/M.7275 6.27, 6.29, 6.51, 6.53, 6.62

Novartis/Hexal, COMP/M.3751 6.58, 6.62

Panasonic Healthcare/Bayer’s Diabetes Care Business, COMP/M.7787 7.13, 7.18, 7.62, 7.92, 7.114

Pfizer/Hospira, M.7559 3.264, 3.265, 3.266, 3.267, 6.9, 6.11, 6.14, 6.15, 6.18, 6.19, 6.20, 6.21, 6.22, 6.24, 6.27, 6.40, 6.64

Pfizer/Wyeth, COMP/M.5476 6.19, 6.27, 6.30, 6.51

Philips/Agilent Health Care Solutions, COMP/M.2256 7.25, 7.29, 7.93

Philips/Intermagnetics, COMP/M.4300 7.25, 7.28, 7.52, 7.90, 7.114

Philips/Marconi Medical Systems, COMP/M.2537 7.25, 7.27, 7.30

Philips/Respironics, COMP/M.5033 7.52, 7.53, 7.59, 7.78, 7.114, 7.115

Procter & Gamble/Teva Pharmaceuticals OTC II, COMP/M.6705 6.40

Proctor & Gamble/Teva OTC Business, COMP/M.6280 6.15, 6.40, 6.58

Reckitt Benckiser/SSL, COMP/M.5953 6.34

Rozier/BHS, COMP/M.4788 6.39

Sanofi-Aventis/Genzyme, COMP/M.5999 6.27, 6.30, 6.59

Sanofi-Aventis/Zentiva, COMP/M.5253 6.9, 6.15, 6.19, 6.30, 6.40, 6.57, 6.60, 6.62

Sanofi-Synthélabo/Aventis, COMP/M.3354 6.27, 6.30

Sanofi/Google/DMI JV, COMP/M.7813 7.13, 7.18, 7.54, 7.92, 7.114, 7.115

Siemens/Bayer Diagnostics, COMP/M.4321 7.13, 7.19

Siemens/Dade Behring, COMP/M.4865 7.11, 7.13, 7.18, 7.19, 7.20

Siemens/Drägerwerk/JV, COMP/M.2861 7.53, 7.78, 7.113

Smith & Nephew/Beiersdorf/JV, COMP/JV.54 7.73, 7.74, 7.75, 7.82, 7.103

Smith & Nephew/Centerpulse, COMP/M.3146 7.33, 7.35, 7.37

Takeda/Nycomed, COMP/M.6278 6.32, 6.42

Telefonica UK/Vodafone UK/Everything Everywhere/JV, COMP M.6317 20.49

Teva/Allergan Generics, M.7746 6.11, 6.13, 6.14, 6.15, 6.27, 6.39, 6.40, 6.44, 6.47

Teva/Barr, COMP/M.5295 6.9, 6.11, 6.17, 6.32, 6.42, 6.55, 6.56, 6.62

Teva/Cephalon, COMP/M.6258 6.34, 6.50, 6.57, 6.59, 6.60

Teva/Ratiopharm, COMP/M.5865 6.5, 6.11, 6.12, 6.19, 6.23, 6.24, 6.25, 6.27, 6.29, 6.30, 6.32, 6.34, 6.35, 6.36, 6.39, 6.41, 6.42, 6.50, 6.55

Thermo Fisher/Phadia, COMP/M.6293 7.11, 7.13, 7.19, 7.81, 7.114

TPG/IMS Health, COMP/M.5736 20.16

Tyco International/US Surgical Corp, COMP/M.1223 – 7.72

Tyco/CR Bard, COMP/M.2505 7.61, 7.81

Tyco/Mallinckrodt, COMP/M.2074 7.61, 7.68, 7.81

Valeant Pharmaceutical International/Bausch & Lomb Holdings, COMP/M.6969 6.5, 6.14, 7.58

Watson/Actavis, COMP/M.6613 6.5, 6.11, 6.34, 6.35, 6.36, 6.37, 6.42, 6.50

Yamanouchi/Fujisawa, COMP/M.3493 6.59

Zimmer/Biomet, COMP/M.7265 6.61, 6.62, 7.11, 7.33, 7.35, 7.36, 7.37, 7.38, 7.39, 7.42, 7.78, 7.93

Zoja/CSC-ICI, IV/26.911 6.38

Notifications

EISAI/Pfizer, Case No IV/36.932/F3 3.221, 5.27

Pfizer + Hoechst Marion Roussel AG, Case No IV/37.590/F3 3.40

NATIONAL COURTS

Australia

Australian Competition and Consumer Commission v. Pfizer Australia Pty Ltd [2015] FCA 113 2.5

Bosnia and Herzegovina

Pharma-Maac, Bosnian Competition Council, Decision 01-02-26-36-19-II/09 8.194

Brazil

Case No 08012.004393/2005-16 18.21

Case No 2007.34.00.043980-0 18.19

Case No 08012.011508/2007-91 18.20

Case No 08012.011615/2008-08 18.25

Case No 08012.007147/2009-40 18.25

Case No 08012.006377/2010-25 18.25

Case No 08012.001693/2011-91 18.25

Case No 08012.005928/2013-12 18.19

China

Rainbow (Ruibang) Medical Equipment & Supplies Co. v. Johnson & Johnson Medical 16.38

Sunyard System Engineering, Anhui AIC, Administrative Penalty Decision [2015] No 2, (18 September 2015) 16.13

France

Autorité de la Concorrence, Decision 07-D-49, 19 December 2007 8.67

Autorité de la Concurrence (France), Decision No 12-D-19, 26 September 2012, relating to practices in the sector and laundering and whitening of tooth 8.158

Autorité de la Concurrence (France), Decision No 13-D-21, 18 December 2013, relating to the practices implemented in the French market for high-dosage buprenorphine marketed in urban areas 8.157

Conseil de la Concurrence, Decision No 07-D-09, 14 March 2013, relating to the practices implemented by the laboratory GlaxoSmithKline in France 8.164

Conseil de la Concurrence, Decision No 09-D-38, 17 December 2009, relating to practices implemented by Ethicon SAS, Tyco Healthcare France and the National Union of Medical Technology industries 8.30, 8.31

Court of Appeals of Paris (France), First Chamber, Section H, 8 of April, 2008 8.172

Emergency transport – Autorité de la Concurrence, Decision No 09-D-35, 25 Novembre 2009, relating to practices implemented in the sector for urgent medical transportation 8.196

Group L’Air Liquide – Conseil de la Concurrence, Decision No 03-D-01, 14 January, 2003, relating to the behaviour of the companies of Groupe L’Air Liquide in the medical gas sector 8.79, 8.94, 8.180

Pharmacists of Low Normandie – Autorité de la Concurrence (France), Decision No 09-D-17, 22 April 2009, relating to the practices of the regional council of the Pharmacists’ Order in Basse Normandie 8.197

Sorin Biomedica France – Autorité de la Concorrence, Decision No 03-D-29, 13 June 2003 8.65, 8.140

Yachting repair in the Mediterranean – Autorité de la Concurrence (France), Decision No 14-D-17, 20 Novembre 2014, relating to the practices implemented in the market for maritime reparations in the Mediterranean 8.198

Germany

Regional Court (Hamburg)

Docket nos. 327 O 67/15 (Hexal), 327 O 143/15 (1A Pharma), 315 O 24/15 (Ratiopharm), 327 O 132/15 (Glenmark) and 327 O 140/15 (Aliud Pharma) 12.78

Supreme Court

Clinical Trials I, 1995 [1997] RPC 623 12.81

Clinical Trials II, 1997 [1998] RPC 423 12.81

Italy

ARCA/Novartis-Italfarmaco, proceedings No 24770, AGCM decision of 29 January 2014 3.222

ARCA/Novartis-Italfarmaco, proceedings No 25056, AGCM decision of 1 August 2014 3.222, 3.255

Pfizer – Antitrust v Pfizer Italia s.r.l., Pfizer Health Ab and Pfizer In, Judgment of the Italian State Council (Consiglio di Stato) of 12 February 2014, Autorità garante della concorrenza e del mercato 5.53, 5.76, 5.80, 5.84, 5.92, 5.95, 5.98

Procedures for the supply of devices for ostomy, Case 17135, AGCM decision of 3 August 2007 8.69

Prodotti disinfettanti, Case 15393, AGCM decision 1639 of 26 April 2006 8.14, 8.83, 8.139, 8.201

Ratiopharm/Pfizer, Case A431, AGCM decision of 11 January 2012 17.67, 18.64

Risonanza Magnetica, Case 20904, AGCM decision I729 of 18 March 2101 – Gara d’appalto per la sanit. per le apparecchiature per la risonanza magnetica 8.100

Roche-Novartis/farmaci Avastin e Lucentis, AGCM decision 24823 of 27 February 2014 3.232

Test diagnostici per diabete, Case 11946, AGCM decision 1461 of 30 April 2003 8.13, 8.41

Mexico

Comision Federal de Competencia Economica (Mexico), Decision of 10 March 2010, Drugs tendered by the Healthcare sector, Case 10-003-2006 8.73

The Netherlands

Novartis AG v. Sun Pharmaceutical Industries (Europe) BV, Ruling of the Court of Appeal of the Hague dated 27 January 2015, case file number: 200.150.713/01 12.78

Poland

Judgment 23 October 2013 of the Polish Supreme Court, Polpharma S.A. Pharmaceutical Works v. Astellas Pharma Inc. Syng. akt IV CSK 92/13 12.88

Portugal

Autoridade da Concorrencia, Decision PRC 2003/06, Abbott Laboratórios, 28 December 2004 8.134

Romania

Eli Lilly – Romanian Competition Council, Decision No 15, 12 March 2008 8.114, 8.120, 8.202

Spain

Abbott Laboratórios – Tribunal de Defensa de la Competencia, Decision PRC 2003/06 of 28 December 2004 8.47

AIO – Decision of the CNMC of 26 May 2016 in Case S/0504/14 17.39

Atención Primaria Mallorca – Decision of the TDC of 11 October 2001 in Case R 452/00 17.75

Baxter – Tribunal de Defensa de la Competencia, Decision PRC 2006/13, 10 December 2010 8.48

Catsalut – Authority of Catalonia, Decision of 9 December 2012 in Case 19/2010 8.199

Citicolina – Decision of the CNMC of 18 June 2014 in Case S/0479/13 17.41, 17.71

Cofarca – Decision of the TDC of 26 May 2003 in Case 539/02 17.74

COFARES/HEFAME – Decision of the Spanish Council of Ministers of 7 July 2006 in Case C96/06 17.90

COFARES/HEFAME – Opinion of the TDC of 6 June 2006 in Case C96/06 17.90

Cofares/Organon – Case R 547/2002 17.56

COFAS – decision of the TDC of 1 September 2000 in Case 470/99 17.33, 17.73

COFAS – Decision of the TDC of 5 May 1997 in Case A 211/97 17.33, 17.73

Colegio de Notarios de Andalucía – Consejo de Defensa de la Competencia de Andalucía, Decision 8 June 2010, Case S/06/2010 8.192

Colegio Farmacéuticos Castilla-La Mancha – Decision of the CNC of 14 March 2009 in Case 639/08 17.37

Compra Mínima Cofas – Decision of the TDC of 26 March 2001 in Case A 277/00 17.33

Decision of the CNMC of 20 July 2017 in Case S/DC/0601/17 17.78

Distribuciones farmacéuticas – Decision of the TDC of 19 February 2004 in Case R 506/01 17.57

EAEPC v. Laboratorios Farmacéuticos, S/DC/0608/17 17.52

EAEPC/Laboratorios farmacéuticos – Decision of the CNC of 14 September 2009 in Case S/0017/07 17.47, 17.50, 17.52

Encomenda de xestión do servizo de protección radiolóxica en hospitais do Servizo Galego de Saúde (Galaria) – Competition Council of Galicia (CGC) – Decision R 7/2014 8.200

Especialidades farmacéuticas genéricas – Decision of the CNC of 23 January 2014 in Case S/0437/12 17.5, 17.32

Estudios de Mercado Industria Farmacéutica – Decision of the CNMC of 13 July 2017 in Case S/DC/0567/15 17.79

Farmacéuticos Formulistas 2 – Decision of the TDC of 23 May 2005 in Case R 626/04 17.76

FARMACIAS, Case SAMUR/01/14 17.37

FEDIFAR – Decision of the TDC of 8 January 2004 in Case 553/03 17.30

FERRER/ROVI – Decision of the CNC of 14 December 2011 in Case C-0411/11 17.86

Football agreements – Spanish National Competititon Authority File S/0006/07, 14 April 2010 20.30, 20.31, 20.32, 20.34

Gases medicinales – Decision of the CNMC of 13 July 2017 in Case S/DC/0561/15 17.40

Genéricos Farmacéuticos – Decision of the TDC of 19 December 2003 in Case R 538/02 17.75

Glaxo Wellcome – Decision of the TDC of 30 July 1998 in Case A 228/97 17.35

GLO BIDCO/MALLINCKRODT – decision of the CNMC of 3 November 2016 in Case C/0803/16 17.92

GRIFOLS – ACTIVOS NOVARTIS – Decision of the CNMC of 25 March 2015 in Case C-0607/14 17.91

IBA MOLECULAR/ITP – Decision of the CNMC of 14 July 2016 in Case C-0766/16 17.92

IBA MOLECULAR/MOLYPHARMA – Decision of the CNMC of 23 October 2014 in Case C-0591-14 17.92

Judgment in Case 555/2013 of the Audiencia Provincial de Madrid of 7 December 2015 17.63

Judgment of the Audiencia Nacional of 13 June 2011 in Case 450/2009 and judgment of the Audiencia Nacional of 5 December 2012 in Case 772/2009 17.49

Judgment of the Audiencia Provincial de Madrid of 7 December 2015 in Case 555/2013 17.53

Judgment of the Juzgado de lo Merantil No 2 of Barcelona of 24 February 2010 17.62

Judgment of the Juzgado de lo Mercantil no 4 of Madrid of 12 March 2013 in Case 187/2007 17.62

Judgment of the Juzgado de Primera Instancia No 6 of Alcobendas of 7 May 2007, confirmed by the judgment of the Audiencia Provincial de Madrid, section 25 of 28 April 2008 17.62

Judgment of the Tribunal Supremo of 28 October 2015 in Case 389/2014 17.12

Judgments of the Tribunal Supremo of 3 December 2014 and 4 March 2016 17.50

Laboratorios Farmacéuticos – Decision of the CNC of 25 September 2008 in Case S/0030/07 17.38, 17.59

Laboratorios Farmacéuticos – Decision of the TDC of 5 December 2001 in Case R 488/01 17.57

Laboratorios Farmacéuticos – Decision of the TDC of 5 December 2001 in Case R 488/01, upheld on appeal by judgment of the Audiencia Nacional of 14 February 2005 in Case 79/2002 17.56

Laboratorios Farmacéuticos, Case R 437/00 17.56

Licitaciones de Carreteras – Comisión Nacional de la Competencia, Decision of 19 October 2011, Case S/0226/10 8.77

Materiales Radioactivos – Tribunal de Defensa de la Competencia, Decision of 16 January 2008, Case 628/07 8.161

Novartis – Decision of 25 April 2011 in Case S/0228/10 17.66

Order of the Juzgado Central de Instrucción No 4 of Madrid of 29 March 2017 in Case 43/2015 17.8

Ortopédicos Castilla-León – Tribunal de Defensa de la Competencia, Decision of 12 December 1996, Case 364/95 8.25, 8.52, 8.102

PFIZER HEALTH AB y PFIZER S.L.U. – Decision of the CNMC of 13 February 2014 in Case S/0441/12 17.91

Pfizer Health AB y Pfizer, S.L.U. – Decision of 13 February 2014 in Case S/0441/12 17.67

Pfizer/Cofares, Case S/DC/0546/15 5.5, 5.12, 10.62, 17.52

Preparados Farmacéuticos – Decision of the CNC of 16 January 2008 in Case 628/07 17.77

Procter & Gamble/Tambrands – Decision of the Spanish Council of Ministers of 14 May 1998 in Case C-29/97 17.89

Procter & Gamble/Tambrands – Opinion of the TDC of 25 May 1998 in Case C-29/97 17.89

Productos Farmacéuticos Genéricos – Decision of the CNC of 24 March 2009 in Case 649/08 17.31

Productos Farmacéuticos Genéricos – Judgment of the Tribunal Supremo of 24 October 2014 in Case 1220/2011 17.31

SAPA/Sociedades SIGMA–TAU – Decision of the CNMC of 24 April 2015 in Case C-0644/15 17.91

SEDIFA y GRUFARMA – Decision of the CNC of 9 June 2010 in Case S/0176/09 17.59

Sistema Andaluz de Salud – Decision of the CNMC of 12 January 2016 in Case S/DC/0523/14 17.27

Spain Pharma/Glaxo – Decision of the TDC of 13 October 2004 in Case R 611/2004 17.58

Spain Pharma/Pfizer – Decision of the CNC of 21 May 2009 in Case 2623/05 17.47, 17.50, 17.52

Spain Pharma/Smithkline – Decision of the TDC of 3 December 2003 in Case R 558/03, confirmed by judgment 56/2004 of the Audiencia Nacional of 10 May 2007 17.57

Spanish Supreme Court (Chamber One) Judgment No 274/11, of 27 April 2011, Cassation appeal No 72/2008 12.24

Spanish Supreme Court, 31 March 2005, Rec. 4574/2002 8.47

Suministro Tiras Reactivas – Decision of the CNMC of 29 October 2015 in Case S/0472/13 17.40

Tribunal de Defensa de la Competencia, Decision of 22 July 2004, Case 565/03 8.51

Turno Rotatorio de Farmacias, Case S/DC/0514/14 17.37

UNITED BUSINESS MEDIA/MEDICOM – Decision of the Service for the Defence of Competition of 21 April 2005 in Case N–04047 17.93

Vaccines against the influenza (Vacunas Antigripales) – Tribunal de Defensa de la Competencia, Decision of 30 September 1998, Case C-395/97 8.45

Vacunas Antigripales – Decision of the TDC of 30 September1998 in Case 395/97 17.36

Wellcome – Decision of 16 July 1998 in Case R 315/98 17.65

United Kingdom

Chancery Division

AAH Pharmaceuticals Ltd v. Pfizer Ltd [2007] EWHC 565 (Ch) 15.146

Improver Corp v. Remington Consumer Product Ltd [1990] F.S.R. 181 12.69, 12.71

Warner-Lambert Company LLC v. Actavis Group PTC [2015] EWHC 2548 (Pat) 12.78

Warner-Lambert Company LLC v. Actavis Group PTC [2015] EWHC 72 (Pat) 12.78

Competition Appeal Tribunal

Apex Asphalt and Paving Co Ltd v. OFT [2005] CAT 4 8.7

Flynn Pharma Ltd, Cases 1275-1276/1/12/17 15.115, 15.117

Generics (UK) Ltd v. CMA [2018] CAT 4 3.150

Generics and Others, Cases 1251–1255/1/12/16 15.95

Genzyme Ltd v. OFT [2004] CAT 4 8.151

Kier Group plc, Kier Regional Limited, Ballast Nedam NV v. OFT [2011] CAT 3 8.9

Makers UK Ltd v. OFT [2007] CAT 11 8.6, 8.7

Teva UK Ltd, Norton Healthcare Ltd v. Reckitt Benckiser Group plc, Reckitt Benckiser Healthcare (UK) Ltd, Case 1213/5/7/13 15.72

Unfair pricing in respect of the supply of Phenytoin Sodium Capsules in the UK, Case CE/9742-13 15.104, 15.117, 15.126

Competition and Markets Authority

Case CE/9855-14 15.123

Case closure statement and guidance on rebates and discounts 26 June 2014, Case CE/9855-14 15.76

Epanutin, Case CE/9742-13 3.244

Paroxetine, Case CE/9531/11 2.9, 15.76, 15.125, 15.126, 18.56

Court of Appeal

Actavis UK Ltd v. Eli Lilly & Co. [2015] EWCA Civ 555 12.71

Argos, Littlewoods and JJB v. OFT [2006] EWCA Civ 1318 8.6

Warner-Lambert Co LLC v. Actavis Group PTC EHF [2015] EWCA Civ 556 12.78

Wheatley v. Drillsafe Ltd [2001] RPC 7 CA (Civ Div) 12.71

House of Lords

Catnic Components Ltd v. Hill & Smith Ltd [1982] RPC 183 12.71

Kirin-Amgen Inc v. Hoechst Marion Roussel Ltd [2004] UKHL 46 12.71

Office of Fair Trading

Abuse of a dominant position by Reckitt Benckiser Healthcare (UK) Limited and Reckitt Benckiser Group plc, CA98/02/2011 15.60, 15.63

Bid rigging in the construction industry in England, 21 September 2009, CE/4327-04 8.56

Exclusionary behaviour by Genzyme Ltd, CA98/3/03 15.44, 15.68

Market sharing agreement and/or concerted practice in relation to the supply of prescription medicines to care homes in England, 20 March 2014, CE/9627/12 8.138

Napp Pharmaceutical Holdings Limited and Subsidiaries v. Director General of Fair Trading, 1001/1/1/01 1.98, 15.37, 15.53, 15.54, 15.57, 15.63, 15.68, 15.137

Napp Pharmaceuticals Holdings Limited and Subsidiaries, CA98/2/2001 15.16, 15.17, 15.18, 15.24, 15.34

Proctor & Gamble, CE/6993/05 15.123

Reckitt Benckiser, CE/8931/08, 13 April 2011 18.64

United States

Abbott Labs. v. Teva Pharms. USA, Inc., 432 F. Supp. 2d 408 (D. Del. 2006) 14.28, 14.30, 14.32, 14.34, 14.35, 14.40, 19.30, 19.32, 19.33, 19.34, 19.35, 19.38, 19.39, 19.40, 19.42, 19.43, 19.44, 19.45

Actos End Payor Antitrust Litigation, In re, 2015 WL 5610752, (2015) 14.21

Aggrenox Antitrust Litigation, In re, 94 F.Supp.3d 225, (2015) 14.22

American Sales Co v. Warner-Chilcott, 2012 WL 4016925, (2013) 14.23

Berkey Photo, Inc. v. Eastman Kodak Co., 603 F.2d 263, (2d Cir. 1979) 14.29, 14.40, 14.45, 16.58

Cardizem CD Antitrust Litigation, In re, 332 F.3d 896 (6th Cir. 2003) 2.135, 14.15

Cipro Cases I & II, In re, 348 P.3d 845, 61 Cal. 4th 116, 187 Cal. Rptr. 3d 632 (2015) 2.146

Cipro Cases I & II, In re, No. 4154 and 4220 (Superior Court for the County of San Diego 18 Nov. 2013) 2.146

Ciprofloxacin Hydrochloride Antitrust Litigation, In re, 544 F.3d 1323 (Fed. Cir. 2008) 14.15

Effexor XR Antitrust Litigation, In re, No. 3:11-cv-05479-PGS-LHG (17 Nov. 2015) 2.142

Federal Trade Commission v. AbbVie Inc., Civil Action No. 14-5151 (E.D. Pa. Aug. 25, 2015) 2.13, 2.145

Federal Trade Commission v. Actavis, Inc. et al., 133 S. Ct. 2223 (2013) 2.6, 2.8, 2.11, 2.58, 2.132, 2.133, 2.135, 2.136, 2.137, 2.138, 2.143, 2.144, 2.146, 2.151, 2.156, 2.167, 14.6, 14.9, 14.14, 14.15, 14.16, 18.47, 18.65, 18.66

Federal Trade Commission v. Cephalon, Inc., Civil Action No. 2: 08-cv-2141 (E.D. Pa. Apr. 15, 2015) 2.146

Federal Trade Commission, Plaintiff v. Endo Pharmaceuticals, Inc., Case Number 2:16–cv–01440 14.21

FTC v. Warner Chilcott Holdings Co. No 1:05-cv 02179-CKK (D.C.C., 23 of October 2006) 8.175

FTC v. Watson Pharm., Inc., 677 F.3d 1298 (11th Cir. 2012), rev’d and remanded sub nom. FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013) 14.15, 14.19, 14.20, 14.21, 14.23, 14.40, 18.51, 18.52, 18.67, 18.68, 18.69, 18.70, 18.75

Illinois Brick v. Illinois, 431 U.S. 720 (1977) 2.8

K-Dur Antitrust Litigation, In re, 686 F.3d 197 (3d Cir. 2012) 2.135, 14.15, 18.67

King Drug Company of Florence v. Smithkline Beecham Corp. (Lamictal), 791 F.3d 388 (3d Cir. 2015) 14.20

Lamictal Direct Purchaser Antitrust Litigation, In re, 18 F.Supp.3d 560, (2014) 14.20

Lamictal, In re, No. 14-1243 (3d. Cir. June 26, 2015) 2.22, 2.144

Lidoderm Antitrust Litigation, In re, 14-md-02521-WHO (N.D. Ca. May 3, 2018) 2.146

Lipitor Antitrust Litigation, In re, 2013 WL 4780496, (2013) 14.22

Lipitor Antitrust Litigation, In re, 46 F. Supp. 3d 523 (D.N.J. 2014) 2.145

Lipitor Antitrust Litigation, In re, 868 F. 3d 231 (3d. Cir. Aug, 212017) 2.145

Loestrin 24 Fe Antitrust Litigation, In re, 45 F.Supp.3d 180, (2014) 14.20

Loestrin 24 Fe Antitrust Litigation, In re, 814 F.3d 538, (1st Cir. 2016) 14.20

Meijer, Inc. v. Barr Pharmaceuticals, Inc., 572 F. Supp. 2d 38, 43 (D.D.C. 2008) 19.24

Mylan Pharmaceuticals v. Warner Chilcott (Doryx) 2015 WL 1736957 (E.D. Pa. 16 Apr. 2015) 19.45, 19.46, 19.47, 19.48

Mylan Pharmaceuticals, Inc v. Warner Chilcott plc, et al. (Case No.2:12-cv-03824-PD) 15.63

Mylan Pharmaceuticls, Inc. v. Warner Chilcott Public Ltd. Co., 2013 WL 5433528, (2013) 14.36, 19.31

New York ex rel. Schneiderman v. Actavis PLC, 787 F.3d 638 (2d Cir. 2015) 2.5

New York v. Actavis (Namenda), 787 F.3d 638 (2d Cir. 2015) 19.24, 19.31, 19.49, 19.350, 19.51, 19.52

New York v. Actavis PLC (Actavis II), 787 F.3d 638 (2d Cir. 2015) 14.42, 14.48

Nexium (Esomeprazole) Antitrust Litigation, In re, 42 F. Supp. 3d 231 (D. Mass. 2014) 2.139, 2.147, 2.149, 2.150

Nexium (Esomeprazole) Antitrust Litigation, In re, 968 F.Supp.2d 367, (2013) 14.20

Nexium (Esomeprazole) Antitrust Litigation, In re, Civil Action No. 12-md-02409-WGY (D. Mass. 7 Aug. 2015) 2.150

Professional Drug Co. Inc. v. Wyeth Inc., 2012 WL 4794587, (2012) 14.22

Roche Products Inc. v. Bolar Pharmaceutical Co. Inc. 733 F.2d 858 (Fed Cir 1984) 12.82

Schering-Plough Corp. v. FTC, 402 F.3d (11th Cir. 2005) 14.15

Solodyn (Minocycline Hydrochloride) Antitrust Litigation, In re, l:14-md-2503-DJC (D. Mass. Apr. 5, 2018) 2.147

Suboxone (Buprenorphine Hydrochloride and Naxolone), In re, Antitrust Litig., 64F.Supp.3d 665 (E.D. Pa. 2014) 14.33, 14.48, 19.31, 19.41, 19.42, 19.45

Tamoxifen Citrate Antitrust Litigation, In re, 466 F3d 187 (2d Cir. 2006) 14.15, 18.69

United States v. Microsoft Corp., 253 F.3d 34, 64 (2001) 14.30, 14.32, 14.40

US FTC v. Actavis, Inc., 570 U.S. 756 (2013) 3.101

US v. Addyston Pipe & Steel Co., 85 F. 271, 283–84 (6th Cir. 1898) 16.58

Valley Drug Co. v. Geneva Pharm., Inc. 344 F.3d 1295 (2003) 2.11, 2.134

Verizon Communications Inc. v. Law Offices of Curtis V. Trinko, LLP, 124 S.Ct. 872, (2004) 14.51, 14.55

Walgreen Co. v. AstraZeneca Pharm. L.P., 534 F. Supp. 2d 146 (2008) 14.32, 14.35, 19.30, 19.37, 19.38, 19.40, 19.43, 19.44, 19.48

Walker process equipment, Inc v. Food Mach and Chem Corp 382 US 172 (1965) 5.20

Wellbutrin XL Antitrust Litigation, In re, 133 F. Supp. 3d 734 (E.D. Pa Sep. 23, 2015) 2.144

Wellbutrin XL Antitrust Litigation, In re, 282 F.R.D 126, (2011) 14.23

Wellbutrin XL Antitrust Litigation, In re, 868 F. 3d 132 (3d. Cir. Aug. 9, 2017) 2.144, 14.23